Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $1.0 million.

  • Crinetics Pharmaceuticals' Depreciation & Amortization (CF) rose 31.43% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 63.08%. This contributed to the annual value of $2.8 million for FY2024, which is 153.64% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) is $1.0 million, which was up 5.53% from $959,000 recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $1.0 million for Q3 2025, and its period low was $215,000 during Q2 2022.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Depreciation & Amortization (CF) value was $753,000 (recorded in 2024), while the average stood at $616,273.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) decreased by 6.52% in 2022, and later spiked by 200.76% in 2024.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Depreciation & Amortization (CF) stood at $235,000 in 2021, then grew by 19.15% to $280,000 in 2022, then fell by 6.43% to $262,000 in 2023, then surged by 200.76% to $788,000 in 2024, then spiked by 31.43% to $1.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.0 million for Q3 2025, versus $959,000 for Q2 2025 and $925,000 for Q1 2025.